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Engineered RNAs carrying substitutions in the integrin receptor-binding Arg-Gly-Asp (RGD)
region of foot-and-mouth disease virus (FMDV) were constructed (aa 141–147 of VP1 capsid
protein) and their infectivity was assayed in cultured cells and suckling mice. The effect of these
changes was studied in the capsid proteins of two FMDVs, C-S8c1, which enters cells through
integrins, and 213hs”, a derivative highly adapted to cell culture whose ability to infect cells using
the glycosaminoglycan heparan sulfate (HS) as receptor, acquired by multiple passage on BHK-
21 cells, has been abolished. The capsid sequence context determined infectivity in cultured cells
and directed the selection of additional replacements in structural proteins. Interestingly, a viral
population derived from a C-S8c1/L144A mutant, carrying only three substitutions in the capsid,
was able to expand tropism to wild-type (wt) and mutant (mt) glycosaminoglycan-deficient CHO
cells. In contrast, the 213hs” capsid tolerated all substitutions analysed with no additional
mutations, and the viruses recovered maintained the ability of the 213hs” parental virus to infect
wt and mt CHO cells. Viruses derived from C-S8c1 with atypical RGD regions were virulent and
transmissible for mice with no other changes in the capsid. Substitution of Asp143 for Ala in the
C-S8c1 capsid eliminated infectivity in cultured cells and mice. Co-inoculation with a neutralizing
monoclonal antibody directed against the type C FMDV RGD region abolished infectivity of C-
S8c1 virus on suckling mice, suggesting that FMDV can infect mice using integrins. Sequence
requirements imposed for viral entry in vitro and in vivo are discussed.
INTRODUCTION
Foot-and-mouth disease virus (FMDV) is a member of the
family Picornaviridae and is the aetiological agent of a
highly contagious and severe disease of cloven-hoofed
animals (Domingo et al., 1990; Pereira, 1981; Sa´iz et al.,
2002). The mature virus particle consists of a non-
enveloped icosahedral capsid enclosing a single-stranded,
positive-sense RNA genome of about 8.5 kb. The capsid is
composed of 60 copies of four virus-encoded structural
proteins, VP1–VP4. A major structural feature of the outer
capsid surface of the virion is a long and exposed flexible
loop, the G–H loop of VP1, which includes a widely
conserved Arg-Gly-Asp (RGD) motif (Acharya et al., 1989;
Fry et al., 2005; Logan et al., 1993). This loop is highly
immunogenic and constitutes one of the major antigenic
sites of FMDV involved in neutralization of viral infectivity
(Mateu & Verdaguer, 2004).
The FMDV RGD motif mediates interaction with RGD-
dependent integrins including avb1, avb3, avb6 and avb8
used as receptors to initiate infection on cultured cells
(Berinstein et al., 1995; Jackson et al., 2000b, 2002, 2004;
Neff et al., 2000). Genetically engineered viruses unable to
infect cultured cells or cause disease in susceptible animals,
carrying deletions or mutations in the RGD motif, have
been reported extensively (Leippert et al., 1997; Mason
et al., 1994; McKenna et al., 1995; Rieder et al., 1996).
Differences in the integrin-binding specificity have been
found for FMDV serotypes (Duque & Baxt, 2003), and the
involvement of the G–H loop residues in infectivity has
been analysed (Mateu et al., 1996). The sequence require-
ments for interaction with different integrins have been
studied using purified human and bovine integrins (Duque
et al., 2004; Jackson et al., 1997, 2000a), as well as
transfected cell lines expressing specific integrins (Burman
et al., 2006; Dicara et al., 2008; Duque & Baxt, 2003;
Jackson et al., 2000b; Rieder et al., 2005).
The high potential of FMDV for variation and adaptation
may lead to modifications affecting receptor usage, tropism
and antigenic diversity (Domingo et al., 2003; Jackson et al.,
2003; Mason et al., 2003; Ruiz-Jarabo et al., 2004).
Adaptation of FMDV to cell culture can result in selection
of variants that use the glycosaminoglycan heparan sulfate
(HS) as receptor (Jackson et al., 1996; Sa-Carvalho et al.,
1997). RGD replacements, such as RGG, RED and GGG, or
the exchange of 8 aa spanning the RGD motif for the FLAG
peptide sequence DYKDDDDK, yielded infectious viruses
only in the context of variants highly passaged on cell
culture (Baranowski et al., 2000, 2001; Martı´nez et al.,
1997; Ruiz-Jarabo et al., 1999). Additionally, after multiple
cytolytic passages, FMDV isolate C-S8c1 acquired sub-
stitutions in the capsid that increased infectivity on BHK-
21 cells and allowed infection of mutant glycosaminogly-
can-deficient CHO cells in an HS-independent pathway.
RGD replacements in these viruses did not affect infectivity
on BHK-21 and CHO cells, suggesting the involvement of
an alternative mechanism of entry independent of RGD
and HS (Baranowski et al., 1998, 2000).
Information currently available indicates that FMDV
utilizes integrins for entry in the natural host, and there
is no evidence of the use of alternative receptors in vivo
(McKenna et al., 1995; Neff et al., 1998). However, the
role of the different integrin receptors on viral tissue
tropism and pathogenesis has not yet been established,
and changes in receptor specificity may also occur during
FMDV replication in vivo. Amino acid substitutions
affecting the RGD motif (R141G) or positions +1 an
+4 (L144P and L147P) have been selected in viruses
escaping an immune response to synthetic peptides in
vaccinated cattle (Taboga et al., 1997; Tami et al., 2003)
and in a C-S8c1 virus adapted to guinea pig (Nu´n˜ez et al.,
2001). Moreover, an engineered chimeric virus carrying
KGE instead of RGD on a type O capsid sequence was able
to replicate and cause mild disease in pigs (Zhao et al.,
2003).
Adult mice are not among the natural hosts of FMDV, but
during the first weeks of life, mice are susceptible to
inoculation of virus particles and viral RNA, inducing a
rapid disease with tremors, ataxia, paralysis of the hind
limbs and death (Baranowski et al., 2003; Skinner, 1951).
The murine model has been characterized and used
extensively for FMDV vaccine development and immun-
ization studies, showing that the virus can replicate upon
experimental inoculation for up to 12–72 h post-inocu-
lation and is subsequently cleared by the adaptive immune
response (Ferna´ndez et al., 1986). Recently, we have shown
that the RGD mutant L147P is unable to grow in cell
culture. However, it can be lethal and transmissible in
d
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suckling mice when inoculated as in vitro-transcribed RNA
derived from an FMDV infectious clone (Baranowski et al.,
2003). In this study, we analysed the effect of amino acid
substitutions in the RGD region within two different capsid
contexts: the C-S8c1 isolate and a second isolate corres-
ponding to virus recovered after multiple passages of C-
S8c1 in BHK-21 cells, which was negatively selected for
2binding to heparin (isolate 213hs ). The viability of the
resultant mutants was assayed in vitro on cultured cells, as
well as in suckling mice by in vivo transfection of the
corresponding RNA transcripts. Our work provides new
data on how sequence changes in the RGD region can
affect virulence in suckling mice and infection of cultured
cells in two different FMDV capsid sequence contexts
resembling field isolates and virus adapted to cell culture,
respectively.
METHODS
Mutagenesis and construction of plasmids. Amino acid sub-
stitutions in the RGD region were introduced into the VP1 capsid
proteins of two different FMDV viruses (Fig. 1). C-S8c1 is a plaque-
purified clone from natural isolate C-Sta Pau Sp/70 (Sobrino et al.,
2 21983). The 213hs capsid sequence corresponds to MARLShs virus,
a monoclonal antibody (mAb)-resistant mutant isolated with mAb
SD6 from C-S8c1 virus after 213 passages on BHK-21 cells and
following negative heparin-binding selection (Baranowski et al.,
1998). Site-directed mutagenesis was carried out using p3242/C-S8c1
(Baranowski et al., 1998) as template for the PCR. Supplementary
Table S1 (available in JGV Online) shows the oligonucleotides used to
introduce specific mutations. PCR fragments were digested with
BssHII and AvrII (hatched boxes in Fig. 1) and ligated into p3242/C-
2S8c1 and p3242/213hs , previously digested with the same enzymes.
2Plasmid p3242/213hs was generated by exchange of the SfiI–BssHII
fragment (nt 2827–3395) carrying mutation K173M in the VP3
protein, conferring the negative heparin-binding phenotype in
MARLS virus (Baranowski et al., 1998), with the corresponding
fragment in plasmid p3242/213 (Baranowski et al., 1998, 2000); to
generate this construct, PCR was performed using p3242/213 as
template and the primers listed in Supplementary Table S1. Finally,
full-length cDNAs carrying mutations in VP1 were constructed by
inserting the corresponding NgoMI fragments from derivatives
2p3242/C-S8c1 and p3242/213hs into the NgoMI site of plasmid
pO1KD3242 (Baranowski et al., 1998).
In vitro transcription and transfection. Plasmids were linearized
by digestion with HpaI and transcripts were generated using SP6 RNA
polymerase (Promega). After transcription, reaction mixtures were
2treated with 1 U RQ1 DNase (mg RNA) 1 (Promega). The RNA
concentration was estimated by agarose gel electrophoresis and
ethidium bromide staining, and transcripts were used for infectivity
assays in mice and cell culture. Semi-confluent monolayers of BHK-
21 cells (~56106), grown in Dulbecco’s modified Eagle’s medium
(Gibco) supplemented with 5% fetal calf serum (Gibco), were
transfected with 5–10 mg RNA using Lipofectin (Invitrogen) (Sa´iz
et al., 2001). After transfection, cells were incubated at 37 uC for up to
6 days until cytopathic effect (CPE) development. Aliquots of 100 ml
of each transfection medium were used to infect approximately
2.56106 fresh BHK-21 cells and wild-type (wt) and mutant (mt)
glycosaminoglycan-deficient pgsA-745 CHO cells. Total RNA was
phenol/chloroform extracted from supernatants of transfected or
infected cells for RT-PCR amplification and subsequent sequencing of
the 2067 bp cDNA fragment corresponding to the capsid genes VP2–
VP1 (Baranowski et al., 2003).
Heparin-binding assay. Binding to heparin was determined using
Sepharose CL-6B beads (Pharmacia Biotech) as described previously
(Baranowski et al., 1998). Briefly, binding was estimated as the ratio
of p.f.u. remaining in the supernatant of serial dilutions of a viral
suspension after incubation with control beads relative to heparin–
Sepharose beads where a ratio of 2 was taken as the limit of positive
detection and ~1 indicated no detectable binding.
Virulence assay on suckling mice. Groups of suckling Swiss mice of
about 1 week old were inoculated intraperitoneally with 100 ml o
different amounts of RNA diluted in PBS containing 20 mg Lipofecti
(Gibco), as described previously (Baranowski et al., 2003). The death of
animals was scored for up to 7 days after inoculation and survivors were
then euthanized. For infectivity transmission assays, crude homogenates
were prepared from dead or euthanized animals previously inoculated
with RNA (Baranowski et al., 2003) and used at a 1 : 100 dilution to
inoculate suckling mice. Total RNA was phenol/chloroform extracted
from mice homogenates for RT-PCR amplification and subsequent
sequencing of the VP2–VP1 region, as above.
For in vivo neutralization assays, mice were injected intraperitoneally
with a mixture containing 50 ml virus at different dilutions and 50 ml
tenfold dilution of supernatant of hybridoma culture of mAb SD6
(Mateu et al., 1987). Neutralizing mAb SD6 was raised against C-S8c1
FMDV and recognizes a non-conserved epitope (aa 138–156) in the
immunogenic region of VP1 including the RGD motif (Mateu et al.,
1987, 1990). After inoculation, dead mice were scored as above. When
mAb SD6 was used under the same conditions for in vitro
neutralization assays on IBRS-2 cells, after incubation at 37 uC for
48 h, 100% neutralization of infectivity was observed for C-S8c1
virus at an m.o.i. of 1 (the highest tested), whilst no neutralizing effect
could be detected for O1K virus, even at the lowest m.o.i. assayed
yielding CPE (m.o.i. of 0.01).
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RESULTS AND DISCUSSION
High tolerance to substitutions in the FMDV RGD
region may generate viruses with expanded
tropism on cell culture, independent of the capsid
sequence context
The amino acid substitutions shown in Fig. 1 were
introduced into full-length cDNA clones containing the
VP1 protein from FMDV C-S8c1 or 213hs2, respectively.
C-S8c1 derives from a pig isolate (Sobrino et al., 1983) and
uses integrins as receptors (Baranowski et al., 1998; Jackson
et al., 2000b). Its derivative, 213, was modified to abolish
the ability to infect cells using HS, acquired after multiple
passage on BHK-21 cells (Baranowski et al., 1998), by
introducing mutation K173M into the VP3 protein to
produce 213hs2. Mutant RNAs derived from full-length
clones (Fig. 1) were transfected into BHK-21 cells, in all
cases generating infectious virus. On average, a complete
CPE was observed at around 24 h post-transfection (p.t.)
for 213hs2 and 4 days for C-S8c1 mutants. When fresh
BHK-21 monolayers were inoculated with aliquots of
transfection medium, CPE was detected within 3 days
post-infection (p.i.).
Sequencing of capsids from the viruses recovered (Table 1)
showed that, in the C-S8c1 sequence context, the D143A
and L144P mutations were not viable, as only the
corresponding revertants were recovered from transfec-
tions. In contrast, H146A replacement was fully tolerated
and complete CPE was observed at around 24–48 h p.t.
with no additional changes in the capsid. Previous data
Fig. 1. Schematic representation of FMDV full-length clones carrying amino acid substitutions in the RGD region. Restriction
sites used for mutagenesis are indicated on the pO1K plasmid. Oligonucleotides used to introduce the specific mutations are
listed in Supplementary Table S1. C-S8c1 genomic regions are represented by open boxes. Hatched boxes indicate the
recombinant PCR fragments inserted, with the mutations listed below. Differences in the amino acid sequences of the chimeric
genomes containing capsids from C-S8c1 or 213hs” virus, respectively, are indicated. Nucleotide numbering is as given by
Escarmı´s et al. (1996).
have shown the relative insensitivity of this position to
peptide inhibition of infectivity (Mateu et al., 1996).
Interestingly, a Thr substitution at position 142 was
observed in viruses obtained after transfection with
G142A RNA as well as following infection, whilst reversion
to G was not detected. Conversion from Ala (GCG) to Thr
(ACG) involves transition GAA, whilst reversion to Gly
(GGG) would need the transversion CAG. Mateu et al.
(1996) demonstrated the high inhibitory effect of peptides
carrying T142 on viral infectivity, suggesting their binding
to cell integrins. Mutants R141A and L147A maintained
the corresponding substitutions, but additional changes
were acquired in the G–H loop and other capsid proteins
after transfection or passage on BHK-21 cells. For mutant
R141A, CPE was complete at 6 days p.t. Sequence mixtures
were detected at three VP1 positions within the G–H loop
and one in the VP2 E–F loop (Acharya et al., 1989); R139
has been found in viruses resistant to SD6 neutralizing
mAb (Martı´nez et al., 1997). After passage in BHK cells,
only the S139R and T148M substitutions were detected in
the capsid. For L147A, in the initial experiment the
substitution was fully tolerated with no other changes until
passage on BHK-21 cells, and cytopathic manifestations
were observed at 2 days p.t. In a second experiment, CPE
was delayed (4 days p.t.) and the sequence mixture found
at position 148 was maintained after infection of BHK-21
cells; A148 has been reported for a 50-passage virus
carrying a GGG motif (Ruiz-Jarabo et al., 1999).
Replacement L147P was not included in this study, as
Nu´n˜ez et al. (2001) previously found it to be deleterious in
the C-S8c1 capsid. Substitution L144A was initially
tolerated as a mixture with Val and, in one case, with an
additional change at position 148. This last virus
population induced complete CPE at 6 days p.t. After
Table 1. Capsid sequences of viruses recovered from transfection of mutant RNAs derived from C-S8c1 and 213hs” clones and
subsequent passage in cell culture
Amino acid residues at the mutated position and additional substitutions found in the capsid proteins are indicated. The transfected mutant
sequence is underlined. Substitutions found that are not in VP1 are indicated with the corresponding capsid protein and position. Sequence
mixtures at single positions are indicated with a solidus. Amino acids corresponding to the C-S8c1 or 213hs2 parental sequence are indicated in
bold. When viral populations recovered from independent experiments showed differences in capsid sequence, these are indicated as (i) and (ii),
respectively.
RNA Transfection Passage in cell culture*
BHK-21 BHK-21 CHO
Wild-type pgsA-745
C-S8c1 C-S8c1 wt + 2 2
C-S8c1/R141A A141, S/R139, T/M148,
H/RD154, VP2 I/FD132
A141, S139R, T148M 2 ND
C-S8c1/G142A T142 T142 2 ND
C-S8c1/D143A D143 + 2 ND
C-S8c1/L144A (i) A/V144 (i) MD/V144 (i) 2 (i) ND
(ii) A/VD144, T/K148d (ii) V144, T/K148 (ii) A144, A145V, VP2
K198Ed
(ii) A144, A145V, VP2
K198E
C-S8c1/L144P L144 + 2 ND
C-S8c1/H146A A146 + 2 ND
C-S8c1/L147A (i) A147 (i) A147, VP3 D9V (i) ND (i) ND
(ii) A147, T/AD148 (ii) A147, T/AD148 (ii) 2 (ii) ND
213hs2 213hs2 wtd + D/GD59 D/GD59
213hs2/R141A A141 + A141, D/GD59, VP3 M/
KD173
A141, D/GD59
213hs2/G142A A142 + A142, D/GD59 A142, D/GD59
213hs2/D143A A143d + A143 A143
213hs2/L144A A144 + A144, D/G59, Q/RD/K200 A144, D/G59, Q/RD/K200
213hs2/L144P P144 + P144, VP3 M/KD173 P144, VP3 M/KD173
213hs2/H146A A146 + A146, VP3 M/KD173 A146, VP3 M/KD173
213hs2/L147A A147 + A147, D/GD59, Q/RD200 A147, D/GD59, Q/R200
213hs2/L147P P147 + P147, D59G P147, D59G
*Results of at least two independent infections. ND, Not done;+, infection yielding cytolytic viruses whose capsid sequences were not determined;
2, no CPE after infection and three blind passages.
DResidue in a proportion of approximately ¢50%.
dViruses with hs2 phenotype confirmed by a heparin–Sepharose binding assay (ratio ~1) as described in Methods.
infection, Met and/or Val was found at this position. V144
has been reported in a virus resistant to SD6 mAb
(Martı´nez et al., 1997), and Met is a residue normally
found at this position in other FMDV serotypes (Burman
et al., 2006). Reversion from Ala (GCG) to Leu (TTG)
would require 2 nt substitutions (a transversion and a
transition, respectively). However, the replacements Ala
(GCG) to Val (GTG) and Val (GTG) to Met (ATG) would
only need a single change (transition). As a mixture of Ala/
Val was firstly detected in transfection supernatants and
then after passage Val/Met mixture was selected, it seems
likely that sequence changes occurred in that order. L144
has been predicted to be a relevant residue for integrin
binding in previous studies using RGD peptides (Burman
et al., 2006; Dicara et al., 2008; Mateu et al., 1996). Our
results showed the relevance of L144 for integrin binding in
the context of the virus. The viability of C-S8c1 virus with
changes in the RGD region has not been reported
previously in cell culture, as only substitutions affecting
integrin recognition domains have been found after
multiple passage in cells (Baranowski et al., 1998;
Martı´nez et al., 1997).
When the capsid sequence of viruses recovered from 213hs2
mutants was determined, significant differences were found
relative to their C-S8c1 counterparts. Indeed, the correspond-
ing Ala or Pro mutations were recovered in all cases from
BHK-21 cells with no other substitutions in the capsid (Table
1). Interestingly, 213hs2 capsid tolerated themutationsD143A
(recovered at 48 h p.t.), L144P and L147P, all of which were
deleterious in the C-S8c1 capsid. Residues at the RGD+1 and
+4 sites have been shown to be major contributors to
integrin-binding specificity (Burman et al., 2006).
In order to explore further the mechanism of viral entry
used by the mutants to infect cultured cells, supernatants
from BHK-21 monolayers transfected with the different
mutants were inoculated onto CHO cells. FMDV isolates
adapted to grow in cell culture can infect wt CHO cells
using HS as a receptor, whilst C-S8c1 virus is unable to
infect this cell line due to restriction of its entry through
integrins. Mutant glycosaminoglycan-deficient pgsA-745
CHO cells were inoculated in the same way to address
whether any of the mutants had acquired the alternative
uncharacterized entry route described for C-S8c1 virus
after 100 passages carrying an RGG mutation and hs2
(Baranowski et al., 1998, 2000). O1K virus derived from
the pO1K full-length clone (able to use HS as a receptor) at
an m.o.i. of 0.1 induced complete CPE in wt CHO at 24–
48 h p.i., whilst no CPE could be detected in mt CHO cells
(data not shown). Interestingly, CPE was detected in wt
and mt CHO cells at 48–72 h p.i. with viruses carrying the
VP1 sequence A/V144 and T/K148 recovered from BHK-21
cells transfected with C-S8c1/L144A. Sequencing of the
viruses generated in CHO cells revealed the presence of a
substitution from Ala to Val at position 145 of the G–H
loop, as reported in a virus resistant to SD6 mAb (Martı´nez
et al., 1997), and an additional change at VP2 position 198
from Lys to Glu (Table 1). With the aim of ruling out the
use of HS as a receptor by these viruses, their hs2
phenotype was confirmed by heparin-binding assays (Table
1). These results showed that C-S8c1 can modify its
receptor usage and expand its tropism to CHO cells with as
few as three changes in the capsid protein. It is worth
noticing that viral populations carrying the A/V144
sequence but lacking the T/K148 mixture were unable to
infect CHO cells, as were the remaining viruses recovered
from BHK-21 transfections (Table 1). Lys at position 198
of the VP2 protein is involved in non-covalent interactions
between pentamer subunits in the C-S8c1 capsid (Mateo et
al., 2003). Substitution of Lys for the negatively charged
Glu may be inducing structural changes in the capsid
affecting receptor interaction.
In contrast, all 213hs2 mutants generated from transfections
induced CPE in wt and mt CHO cells at 24–48 h p.i.
Although maintaining the corresponding mutations in the
RGD region, sequence mixtures or substitutions were
detected at positions 59 and 200 of VP1 and position 173
of VP3 throughout the mutants capsids (Table 1). Position
59 is part of the B–C loop at the amino terminus of VP1
(Acharya et al., 1989), in which mutations perturbing the
stability of the G–H loop have been reported (Parry et al.,
1990). Q200R substitution, in antigenic site C (Mateu &
Verdaguer, 2004), was selected in viruses carrying a FLAG
peptide sequence after passage in BHK-21 (Baranowski et al.,
2001). D/G59 and Q/R200mixtures were also found in IBRS-
2 cells transfected with some of the 213hs2mutants (data not
shown), suggesting that these substitutions are not linked
specifically to replication in CHO cells. In some of the viruses
recovered from wt and mt CHO cells, partial reversions to
Lys at position 173 in the VP3 protein were detected (Table
1). As pgsA-745 CHO cells are HS deficient, no relevant
contribution to viral entry through HS can be expected for
this sequence mixture in these viruses.
Viruses recovered from transfection of 213hs2/D143A
RNA infected wt and mt CHO cells with no other changes
in the capsid. This mutation was lethal in the C-S8c1
context, presumably abolishing interaction with integrins.
The hs2 phenotype of 213hs2/A143 viruses was confirmed
by a heparin–Sepharose binding assay (Table 1). This result
demonstrated that these viruses can infect CHO cells using
an RGD- and HS-independent route. Binding to heparin in
viruses recovered from transfections with 213hs2/wt RNA
was also not detected (Table 1). Interestingly, unlike
213hs2 viruses, a mAb-resistant viral population generated
after passage 213 (MARLS) lost infectivity in wt and mt
CHO cells after selection by 10 rounds of heparin–
Sepharose binding (MARLShs2) (Baranowski et al.,
1998). The contribution of other sequences in the viral
genome or present in the capsid at amounts below
detection levels for this difference between 213hs2 and
MARLShs2 viruses cannot be ruled out.
Our results showed that FMDV parental genomes can
accommodate substitutions in the RGD region, whilst
additional changes in flanking residues are, in some cases,
selected. However, aa 143 remained resistant to changes,
probably due to structural constraints essential for integrin
binding in the wt capsid sequence. In contrast, viral genomes
highly adapted to cell culture were able to incorporate these
mutations with no other changes in the capsid, maintaining
their capacity to enter cells using the non-RGD, non-HS
route. In fact, this still uncharacterized route would be the
only possible way known so far to enter BHK-21 cells for
D143A, L144P and L147P mutants. Replacements selected in
C-S8c1 and 213hs2 mutant capsids in cultured cells were
different, showing substantial flexibility to changes that are
accommodated differently depending on the capsid context.
The concept of tolerance to a given mutation is therefore
relative and depends on the capsid sequence.
Virulence on suckling mice is only abolished by
replacements in position D143 of the RGD region
To address the effect of substitutions in the RGD region on
FMDV infectivity and transmission in suckling mice, the
different mutant RNAs were assayed by intraperitoneal
injection, as described previously (Baranowski et al., 2003)
(Table 2). In the C-S8c1 context, all of the RNAs except
mutant D143A were infectious, although with different
levels of lethality. Transcripts derived from the parental full-
length clone pO1K/C-S8c1 (Fig. 1), used to construct all of
the C-S8c1 mutants assayed here, were fully infectious at
RNA amounts of approximately 1 mg (Baranowski et al.,
2003). D143A transcripts up to 100 mg failed to kill any
mice. Several inoculations with homogenates from either an
animal that showed early signs of disease after RNA
injection or an asymptomatic mouse also failed to kill.
Thus, the presence of D143 seems to be a strict requirement
for C-S8c1 infectivity in mice, as observed in BHK-21 cells
(Table 1). This is in agreement with the high level of
conservation of residue D143 among natural FMDV isolates
(Carrillo et al., 2005) and supports its relevance in binding
to integrin receptors. Very low levels of infectivity were
exhibited by R141A RNA. Only one animal died after
inoculation with 10 mg of transcript, but homogenates from
this mouse were lethal in a new round of inoculation,
indicating the presence of infectious virus. This suggests that
R141 can occasionally become dispensable and is consistent
Table 2. Infectivity of RNA transcripts in suckling mice and
virulence of resultant viruses
Amount of RNA
inoculated
No. dead animals/no. inoculated
RNA infectivity* VirulenceD
C-S8c1/R141A
50 mg 0/2
10 mg 1/11 (4) 5/6
5 mg 0/6 (1)
1 mg 0/10
500 ng 0/4
200 ng 0/2
100 ng 0/2
C-S8c1/G142A
20 mg 5/5 3/3
10 mg 4/5
5 mg 1/1
1 mg 0/5
500 ng 0/4
200 ng 0/2
100 ng 0/2
C-S8c1/D143A
100 mg 0/2 (1) 0/3
50 mg 0/2 0/3
10 mg 0/1
1 mg 0/5
500 ng 0/4
200 ng 0/2
100 ng 0/2
C-S8c1/L144A
50 mg 2/2
10 mg 4/5 3/3
5 mg 4/4
1 mg 3/10 (1)
500 ng 0/9 (2)
200 ng 0/5
100 ng 0/4
Amount of RNA
inoculated
No. dead animals/no. inoculated
RNA infectivity* VirulenceD
C-S8c1/L144P
50 mg 1/2 (1)
10 mg 2/5 1/3
5 mg 1/5 (1)
1 mg 4/6 (1)
500 ng 1/5
200 ng 0/2
100 ng 0/2
C-S8c1/H146A
10 mg 1/4 (2) 1/3
5 mg 2/5
1 mg 0/5
C-S8c1/L147A
10 mg 2/2 3/3
5 mg 3/3
1 mg 2/5
*No. of dead/no. of inoculated animals after inoculation with the
corresponding RNAs. Transcripts derived from parental full-length
clone 213hs2 and the 213hs2/D143A mutant up to 20 mg failed to kill
any mice. The number of animals showing early signs of disease
(transient tremors and ataxia) and subsequent healing is shown in
parentheses.
DNo. of dead/no. of inoculated animals after inoculation with
homogenates from single animals from the corresponding RNA-
inoculated mice. In groups including survivors after RNA inoculation,
homogenates were prepared from a dead mouse (Baranowski et al.,
2003). For the C-S8c1/D143A mutant, two mice were euthanized,
including one that showed early signs of disease.
Table 2. cont.
with previous data in vivo showing that viruses carrying
SGD or GGD could be isolated from cattle infected with
FMDV type A and C isolates, respectively (Rieder et al.,
2005; Taboga et al., 1997; Tami et al., 2003). H146A RNA
killed mice with 5 mg of transcript, and homogenates from
dead mice killed only one of the three animals inoculated.
This result contrasted with the absolute tolerance to the
H146A mutation in cultured cells (Table 1), suggesting that
this replacement affects fitness differently in mice compared
with cell culture. The substitutions G142A, L144A and
L147A were well tolerated with RNA amounts ¡5 mg able
to kill approximately 50% of the inoculated animals. L144P
RNA was lethal from 0.5 mg but none of the doses assayed
could kill 100% of the inoculated mice. We previously
described the infectivity of L147P transcripts in mice
(Baranowski et al., 2003). As mentioned above, and again
consistent with the lethality patterns obtained in mice,
L144P and L147P have both been found in viable viruses
replicating in target species (Taboga et al., 1997; Tami et al.,
2003).
The capsid sequence of viruses generated after RNA
inoculation was determined as above from the mice
homogenates used for virulence assays. In all cases, the
capsid sequence was maintained. Only for the L144P
mutant was an additional replacement of L201I detected in
the VP1 carboxyl terminus within antigenic site C (Mateu
& Verdaguer, 2004). Substitution R141A was confirmed,
with no additional changes, in viruses infecting one of the
five mice that died in the virulence assay. For D143A, viral
RNA could not be amplified by RT-PCR, confirming that
no infectious virus was generated.
When transcripts derived from parental full-length clone
213hs2 and the 213hs2/D143A mutant were assayed,
amounts up to 20 mg were innocuous for mice (data not
shown). The high level of attenuation found for these
genotypes in mice is in agreement with previous reports
showing the attenuated phenotype in vivo conferred by
mutations selected during serial passage in cultured cells
(Neff et al., 1998; Sa-Carvalho et al., 1997). Indeed, we have
shown previously the lack of infectivity in suckling mice of
FMDV O1K transcripts bearing an H56R substitution in
the VP3 protein, selected in type O isolates upon passage in
cell culture (Baranowski et al., 2003). Interestingly,
supernatant from BHK-21 cells transfected with 213hs2
transcripts inoculated into mice resulted in 100% lethality
at a tenfold dilution (data not shown). The viruses
recovered from dead mice had amino acid mixtures of
VP1 R197 with Ser and VP3 K218 with Arg and Gln
throughout the capsid, suggesting the relevance of these
positions to regaining infectivity in vivo. However, several
trials to infect mice with supernatants from 213hs2/
D143A-transfected cells failed to kill any mice (not shown).
Although additional effects on the viral cycle of the
replacements analysed here cannot be ruled out, our
results show that substitutions in the RGD region are
differentially tolerated in cultured cells and animals,
suggesting different sequence requirements for viral entry
in vitro and in vivo. These constraints can be modulated
efficiently in cultured cells by the surrounding capsid
sequence, and, in some cases, the viral population rapidly
selects additional changes in the capsid (see C-S8c1
mutants R141A, L144A and L147A). However, mutant
viruses with non-canonical RGDs were infectious for mice
with no or few changes in their capsids (Table 2 and L144P
mutant, respectively). Some of these viruses showed
patterns of lethality not directly dependent on the
inoculation dose, probably due to suboptimal binding
affecting integrin affinity and/or specificity.
The integrin receptor avb6 is expressed constitutively on
epithelial cells targeted by FMDV in cattle and sheep
(Brown et al., 2006; Monaghan et al., 2005). Similarly,
avb6 in mouse epithelia is highly expressed in the lung,
skin and kidney during organogenesis, although barely
detectable in adult animals, but is rapidly and transiently
induced in response to local injury or inflammation
(Huang et al., 1996). Activation in vivo of different
integrin species during infection has been suggested as a
mechanism to switch on receptors for viral entry (Luo et
al., 2007). Although there is no direct experimental
evidence on receptors used by FMDV in mice, and no
extrapolation regarding virulence or pathology can be
made to natural viral hosts at present, our results for the
susceptibility of suckling mice to FMDV RNAs were in all
cases consistent with information available on their
viability in target species (see the L144P and L147P
mutants). In fact, infectivity in primary bovine thyroid
cell cultures of guinea pig-adapted FMDV, carrying the
L147P mutation, can be specifically inhibited with anti-
avb6 mAb, strongly suggesting that this virus, infectious
for pigs and suckling mice, is using this integrin as a
receptor in the animal host (Nu´n˜ez et al., 2007). With the
aim of testing the involvement of the RGD region in
FMDV virulence in mice, we tried in vivo neutralization
assays with virus preparations co-inoculated with mAb
SD6 (Table 3). Neutralizing mAb SD6 recognizes the
immunogenic region of VP1 spanning aa 138–156 in the
G–H loop enclosing the RGD (Mateu et al., 1987, 1990).
The effect of blockage of infectivity was dramatic for
Table 3. Infectivity of C-S8c1 in mice is abolished by
incubation with specific neutralizing mAb SD6 binding to the
RGD region
No. of dead/no. of inoculated animals at 4 days p.i. with dilutions of
O1K or C-S8c1 virus (5.46107 and 2.76106 p.f.u. ml21, respectively)
in the presence or absence of SD6 mAb.
SD6 O1K C-S8c1
1023 1025 1022 1023 1024 1025
2 2/5 0/5 5/5 5/5 5/5 5/5
+ 3/5 2/5 0/5 0/5 0/5 0/5
C-S8c1 virus against which the mAb had been elicited.
However, the virulence of O1K virus was not affected by
the presence of the mAb, which is unable to bind
heterologous type O isolates. As monovalent steric
inhibition of receptor binding is the major mechanism
by which antibody SD6 neutralizes FMDV infectivity
(Verdaguer et al., 1997), these results indicate that viral
entry in mice is determined by capsid sequences
overlapping the binding area of SD6, mainly the RGD
region, supporting the use of integrins for FMDV
infection in suckling mice. In agreement with this, the
patterns of lethality observed in mice for the different
transcripts were, in all cases, consistent with previous
data in vivo regarding the corresponding altered posi-
tions. Therefore, we believe that the RNA virulence assay
in suckling mice can be widely used for screening of
FMDV genotypes that are viable in vivo. However, further
characterization of the integrins expressed in mice will
help to correlate receptor usage in mice compared with
the natural host species.
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